Norditropin NordiFlex 10 mg/1.5 ml נורווגיה - נורבגית - Statens legemiddelverk

norditropin nordiflex 10 mg/1.5 ml

novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 10 mg/1.5 ml

Actikerall 5 mg/ g / 100 mg/ g נורווגיה - נורבגית - Statens legemiddelverk

actikerall 5 mg/ g / 100 mg/ g

almirall hermal gmbh - fluorouracil / salisylsyre - liniment, oppløsning - 5 mg/ g / 100 mg/ g

Norditropin NordiFlex 10 mg/1.5 ml נורווגיה - נורבגית - Statens legemiddelverk

norditropin nordiflex 10 mg/1.5 ml

novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 10 mg/1.5 ml

Norditropin NordiFlex 5 mg/1.5 ml נורווגיה - נורבגית - Statens legemiddelverk

norditropin nordiflex 5 mg/1.5 ml

novo nordisk a/s - somatropin - injeksjonsvæske, oppløsning i ferdigfylt penn - 5 mg/1.5 ml

Alacare 8 mg נורווגיה - נורבגית - Statens legemiddelverk

alacare 8 mg

photonamic gmbh & co. kg - 5-aminolevulinsyre - medisinert plaster - 8 mg

Pamorelin 22.5 mg נורווגיה - נורבגית - Statens legemiddelverk

pamorelin 22.5 mg

institut produits synthèse (ipsen) ab - triptorelinembonat - pulver og væske til depotinjeksjonsvæske, suspensjon - 22.5 mg

Sogroya האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - vekst - hypofysiske og hypotalamiske hormoner og analoger - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Osurnia האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

osurnia

dechra regulatory b.v. - betamethasone acetate, terbinafine, florfenicol - kortikosteroider og antiinfectives i kombinasjon - hunder - behandling av akutt otitis externa.

Voxzogo האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

voxzogo

biomarin international limited - vosoritide - achondroplasia - legemidler til behandling av bein sykdommer - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Imcivree האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

imcivree

rhythm pharmaceuticals netherlands b.v. - setmelanotide - fedme - antiobesity preparater, ekskl. diettprodukter - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.